| NCT03364231 |
Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03364231 |
Recruiting |
TG Therapeutics, Inc. |
2020-11-01 |
| NCT03410901 |
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03410901 |
Recruiting |
Stanford University |
2020-10-09 |
| NCT03820817 |
Rifaximin in Patients With Monoclonal Gammopathy |
https://ClinicalTrials.gov/show/NCT03820817 |
Recruiting |
Emory University |
2020-11-30 |
| NCT03335098 |
Study of VTD in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03335098 |
Recruiting |
Seoul National University Hospital |
2020-12-31 |
| NCT03333486 |
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer |
https://ClinicalTrials.gov/show/NCT03333486 |
Recruiting |
Roswell Park Cancer Institute |
2022-09-06 |
| NCT03332173 |
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM) |
https://ClinicalTrials.gov/show/NCT03332173 |
Active, not recruiting |
BeiGene |
2020-12-31 |
| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
https://ClinicalTrials.gov/show/NCT03314974 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2025-01-10 |
| NCT03277729 |
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03277729 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-11-16 |
| NCT03225716 |
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03225716 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-01-31 |
| NCT03192397 |
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03192397 |
Recruiting |
Roswell Park Cancer Institute |
2021-07-01 |
| NCT03187262 |
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03187262 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-01-31 |
| NCT03162536 |
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03162536 |
Recruiting |
ArQule |
2021-12-31 |
| NCT03133221 |
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03133221 |
Recruiting |
University of Maryland, Baltimore |
2021-03-31 |
| NCT03053440 |
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström’s Macroglobulinemia (WM) |
https://ClinicalTrials.gov/show/NCT03053440 |
Active, not recruiting |
BeiGene |
2021-06-30 |
| NCT03037645 |
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers |
https://ClinicalTrials.gov/show/NCT03037645 |
Recruiting |
Sunesis Pharmaceuticals |
2020-12-31 |
| NCT03019666 |
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
https://ClinicalTrials.gov/show/NCT03019666 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-09-30 |
| NCT03015896 |
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03015896 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-04-30 |
| NCT03010358 |
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03010358 |
Active, not recruiting |
OHSU Knight Cancer Institute |
2022-02-28 |
| NCT02991638 |
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers |
https://ClinicalTrials.gov/show/NCT02991638 |
Recruiting |
The University of Hong Kong |
2020-12-31 |
| NCT02962401 |
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02962401 |
Active, not recruiting |
French Innovative Leukemia Organisation |
2020-08-31 |
| NCT02952508 |
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) |
https://ClinicalTrials.gov/show/NCT02952508 |
Recruiting |
Cellectar Biosciences, Inc. |
2020-07-31 |
| NCT02950220 |
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02950220 |
Completed |
Ohio State University Comprehensive Cancer Center |
2018-11-19 |
| NCT02933320 |
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia |
https://ClinicalTrials.gov/show/NCT02933320 |
Recruiting |
Cancer Research UK |
2022-01-31 |
| NCT02916979 |
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators’ Expression in Allogeneic SCT Using FluBuATG |
https://ClinicalTrials.gov/show/NCT02916979 |
Active, not recruiting |
Dartmouth-Hitchcock Medical Center |
2020-12-31 |
| NCT02722668 |
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
https://ClinicalTrials.gov/show/NCT02722668 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2028-05-31 |
| NCT02677324 |
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02677324 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-03-31 |
| NCT02669017 |
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) |
https://ClinicalTrials.gov/show/NCT02669017 |
Completed |
ADC Therapeutics S.A. |
2019-02-21 |
| NCT02661035 |
Allo HSCT Using RIC for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT02661035 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-03-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02604511 |
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom’s Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing |
https://ClinicalTrials.gov/show/NCT02604511 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-02-28 |
| NCT04116437 |
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment |
https://ClinicalTrials.gov/show/NCT04116437 |
Recruiting |
BeiGene |
2022-09-30 |
| NCT02566265 |
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients |
https://ClinicalTrials.gov/show/NCT02566265 |
Completed |
Yale University |
2017-10-31 |
| NCT01381692 |
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01381692 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-07-23 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02400437 |
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02400437 |
Completed |
Dana-Farber Cancer Institute |
2019-11-30 |
| NCT02371148 |
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia’s |
https://ClinicalTrials.gov/show/NCT02371148 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2017-11-30 |
| NCT02363439 |
Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401 |
https://ClinicalTrials.gov/show/NCT02363439 |
Completed |
Idera Pharmaceuticals, Inc. |
2016-12-31 |
| NCT02362035 |
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02362035 |
Active, not recruiting |
Acerta Pharma BV |
2021-05-31 |
| NCT02339922 |
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02339922 |
Active, not recruiting |
University of Washington |
2025-01-06 |
| NCT02332980 |
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT02332980 |
Recruiting |
Mayo Clinic |
2021-01-05 |
| NCT02302469 |
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02302469 |
Completed |
University Hospital, Lille |
2017-03-31 |
| NCT02257242 |
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02257242 |
Recruiting |
Brown University |
2020-12-31 |
| NCT02242045 |
Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02242045 |
Completed |
Gilead Sciences |
2014-12-25 |
| NCT02213913 |
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02213913 |
Recruiting |
University of Chicago |
2020-07-29 |
| NCT02180724 |
An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02180724 |
Active, not recruiting |
Acerta Pharma BV |
2018-02-28 |
| NCT02165397 |
Ibrutinib With Rituximab in Adults With Waldenström’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02165397 |
Completed |
Pharmacyclics LLC. |
2019-11-07 |
| NCT02153580 |
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02153580 |
Recruiting |
City of Hope Medical Center |
2021-12-31 |
| NCT02071888 |
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors |
https://ClinicalTrials.gov/show/NCT02071888 |
Completed |
Calithera Biosciences, Inc |
2016-04-30 |
| NCT01314014 |
Imexon for Relapsed Follicular and Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT01314014 |
Completed |
University of Rochester |
2013-03-31 |
| NCT01282424 |
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT01282424 |
Completed |
Gilead Sciences |
2018-05-02 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02049541 |
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02049541 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2018-09-12 |
| NCT04018248 |
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) |
https://ClinicalTrials.gov/show/NCT04018248 |
Recruiting |
Boryung Pharmaceutical Co., Ltd |
2023-12-31 |
| NCT04273139 |
Ibrutinib + Venetoclax in Untreated WM |
https://ClinicalTrials.gov/show/NCT04273139 |
Recruiting |
Dana-Farber Cancer Institute |
2023-06-01 |
| NCT03479268 |
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03479268 |
Recruiting |
City of Hope Medical Center |
2022-04-01 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01955499 |
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01955499 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT01815749 |
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01815749 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-31 |
| NCT01805375 |
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies |
https://ClinicalTrials.gov/show/NCT01805375 |
Completed |
Cancer Research UK |
2017-12-14 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01804686 |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
https://ClinicalTrials.gov/show/NCT01804686 |
Enrolling by invitation |
Janssen Research & Development, LLC |
2026-12-31 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01788020 |
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01788020 |
Active, not recruiting |
University of Ulm |
2018-11-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01744912 |
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01744912 |
Completed |
TG Therapeutics, Inc. |
2014-05-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01647971 |
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01647971 |
Completed |
TG Therapeutics, Inc. |
2015-05-31 |
| NCT01592981 |
Randomised Trial in Waldenstrom’s Macroglobulinaemia |
https://ClinicalTrials.gov/show/NCT01592981 |
Active, not recruiting |
University College, London |
2017-03-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01527045 |
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01527045 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-10-31 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01479842 |
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01479842 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2014-03-31 |
| NCT01474681 |
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01474681 |
Completed |
Novartis |
2016-10-03 |
| NCT01470196 |
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01470196 |
Completed |
Dana-Farber Cancer Institute |
2016-09-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01416428 |
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01416428 |
Completed |
Amgen |
2019-08-12 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01351935 |
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01351935 |
Completed |
Celgene |
2015-06-26 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04440059 |
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT04440059 |
Recruiting |
Beijing InnoCare Pharma Tech Co., Ltd. |
2021-10-31 |
| NCT04274738 |
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom’s Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 |
https://ClinicalTrials.gov/show/NCT04274738 |
Recruiting |
X4 Pharmaceuticals |
2021-06-30 |
| NCT04191187 |
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04191187 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-12-31 |
| NCT04115059 |
Dasatinib In Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT04115059 |
Recruiting |
Dana-Farber Cancer Institute |
2022-03-01 |
| NCT04062448 |
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom’s Macroglobulinemia (WM) |
https://ClinicalTrials.gov/show/NCT04062448 |
Recruiting |
Janssen Pharmaceutical K.K. |
2023-06-01 |
| NCT04042376 |
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom’s Macroglobulinemia (WM) |
https://ClinicalTrials.gov/show/NCT04042376 |
Recruiting |
Janssen Research & Development, LLC |
2023-12-31 |
| NCT03884998 |
Copanlisib and Nivolumab in Treating Participants With Richter’s Transformation or Transformed Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03884998 |
Recruiting |
OHSU Knight Cancer Institute |
2021-01-06 |
| NCT03833180 |
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03833180 |
Recruiting |
VelosBio Inc. |
2021-03-31 |
| NCT03771157 |
Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors |
https://ClinicalTrials.gov/show/NCT03771157 |
Active, not recruiting |
University of Rochester |
2019-08-28 |
| NCT03740529 |
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL |
https://ClinicalTrials.gov/show/NCT03740529 |
Recruiting |
Loxo Oncology, Inc. |
2020-10-31 |
| NCT03697356 |
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03697356 |
Recruiting |
Kosin University Gospel Hospital |
2021-10-31 |
| NCT03679455 |
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 |
https://ClinicalTrials.gov/show/NCT03679455 |
Recruiting |
Polish Myeloma Consortium |
2019-04-30 |
| NCT03674411 |
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy |
https://ClinicalTrials.gov/show/NCT03674411 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-07-31 |
| NCT03630042 |
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia |
https://ClinicalTrials.gov/show/NCT03630042 |
Recruiting |
University College, London |
2021-03-31 |
| NCT03620903 |
Efficacy of First Line B-RI for Treatment Naive Waldenström’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03620903 |
Recruiting |
University of Ulm |
2022-03-31 |
| NCT03601819 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT03601819 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-09-30 |
| NCT03506373 |
Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT03506373 |
Recruiting |
Mayo Clinic |
2025-05-01 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01251575 |
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01251575 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-11-23 |
| NCT01239875 |
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01239875 |
Completed |
Mayo Clinic |
2015-11-24 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01231412 |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01231412 |
Completed |
Fred Hutchinson Cancer Research Center |
2016-10-08 |
| NCT01209871 |
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma |
https://ClinicalTrials.gov/show/NCT01209871 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-02-20 |
| NCT01198067 |
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01198067 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01125293 |
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01125293 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-02-29 |
| NCT01118689 |
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01118689 |
Completed |
Millennium Pharmaceuticals, Inc. |
2013-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01109069 |
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01109069 |
Completed |
Pharmacyclics LLC. |
2019-04-26 |
| NCT01076543 |
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01076543 |
Completed |
National Cancer Institute (NCI) |
2017-12-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01008462 |
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01008462 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-06-30 |
| NCT00976248 |
Everolimus (RAD001) in Primary Therapy of Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00976248 |
Completed |
Dana-Farber Cancer Institute |
2016-07-31 |
| NCT00936611 |
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00936611 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-02-29 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00861510 |
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00861510 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-10-19 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00832234 |
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00832234 |
Completed |
European Myeloma Network |
2010-06-30 |
| NCT02640287 |
Expression of Ku70/XRCC6 in Waldenström’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT02640287 |
Recruiting |
Central Hospital, Nancy, France |
2019-11-02 |
| NCT00811733 |
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00811733 |
Completed |
GlaxoSmithKline |
2011-06-01 |
| NCT00807677 |
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00807677 |
Completed |
Millennium Pharmaceuticals, Inc. |
2012-09-30 |
| NCT00801281 |
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. |
https://ClinicalTrials.gov/show/NCT00801281 |
Completed |
Polish Lymphoma Research Group |
2017-06-25 |
| NCT03246906 |
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03246906 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-08-15 |
| NCT03147885 |
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03147885 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-06-30 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01614821 |
Ibrutinib (PCI-32765) in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT01614821 |
Completed |
Dana-Farber Cancer Institute |
2016-09-09 |
| NCT00789776 |
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00789776 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-05-31 |
| NCT00783367 |
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00783367 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2012-11-14 |
| NCT00777738 |
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00777738 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2012-08-31 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00723099 |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00723099 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-07-31 |
| NCT00720135 |
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00720135 |
Completed |
City of Hope Medical Center |
2014-07-31 |
| NCT00719888 |
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
https://ClinicalTrials.gov/show/NCT00719888 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-12-31 |
| NCT00718419 |
A Study for Patients That Have Been Previously Been Treated in Waldenstrom’s Macroglobulinemia or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00718419 |
Completed |
Eli Lilly and Company |
2010-09-30 |
| NCT00711828 |
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00711828 |
Completed |
Mayo Clinic |
2013-11-30 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00644189 |
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00644189 |
Active, not recruiting |
Massachusetts General Hospital |
2013-12-31 |
| NCT00621452 |
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00621452 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-01-31 |
| NCT00608374 |
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma |
https://ClinicalTrials.gov/show/NCT00608374 |
Completed |
National Cancer Institute (NCI) |
2009-12-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00566332 |
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00566332 |
Completed |
French Study Group on Chronic Lymphoid Leukemia |
2009-09-30 |
| NCT00546793 |
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL |
https://ClinicalTrials.gov/show/NCT00546793 |
Completed |
Immunomedics, Inc. |
2013-03-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00492050 |
Bortezomib and Rituximab for Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00492050 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-02-28 |
| NCT00481871 |
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
https://ClinicalTrials.gov/show/NCT00481871 |
Completed |
Acrotech Biopharma LLC |
2011-05-31 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00438880 |
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00438880 |
Completed |
Mayo Clinic |
2010-10-31 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT00422799 |
Combination Bortezomib and Rituximab in Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00422799 |
Completed |
Dana-Farber Cancer Institute |
2015-10-09 |
| NCT00422656 |
Perifosine in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00422656 |
Completed |
Dana-Farber Cancer Institute |
2009-06-30 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00290472 |
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00290472 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00281983 |
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00281983 |
Completed |
German CLL Study Group |
NA |
| NCT00273936 |
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00273936 |
Completed |
Vertex Pharmaceuticals Incorporated |
NA |
| NCT00250926 |
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00250926 |
Completed |
Dana-Farber Cancer Institute |
2007-03-31 |
| NCT00244855 |
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00244855 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-12-31 |
| NCT00165295 |
Sildenafil Citrate in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00165295 |
Completed |
Dana-Farber Cancer Institute |
2007-06-30 |
| NCT00150462 |
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00150462 |
Completed |
Amgen |
2009-10-31 |
| NCT00146055 |
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood |
https://ClinicalTrials.gov/show/NCT00146055 |
Completed |
University of Michigan Rogel Cancer Center |
2004-11-30 |
| NCT00142181 |
Phase II Study of Campath-1H Antibody to Treat Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00142181 |
Completed |
Dana-Farber Cancer Institute |
2005-10-31 |
| NCT00142155 |
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00142155 |
Completed |
Dana-Farber Cancer Institute |
2007-03-31 |
| NCT00142129 |
Bortezomib (Velcade) in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00142129 |
Completed |
Dana-Farber Cancer Institute |
2007-06-30 |
| NCT00142116 |
Thalidomide and Rituximab in Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00142116 |
Completed |
Dana-Farber Cancer Institute |
2004-02-29 |
| NCT00119392 |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00119392 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00118170 |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function |
https://ClinicalTrials.gov/show/NCT00118170 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00110071 |
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00110071 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00096161 |
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00096161 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-02-28 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003416 |
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00003416 |
Completed |
Southwest Oncology Group |
2000-08-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00083707 |
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00083707 |
Completed |
University of Arkansas |
NA |
| NCT00082784 |
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT00082784 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00004107 |
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00004107 |
Completed |
Garden State Cancer Center at the Center for Molecular Medicine and Immunology |
2001-05-31 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00005609 |
Rituximab in Treating Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00005609 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00004889 |
Rituximab in Treating Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00004889 |
Completed |
Jonsson Comprehensive Cancer Center |
2002-01-31 |
| NCT00075478 |
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00075478 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-02-28 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00068315 |
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00068315 |
Completed |
National Cancer Institute (NCI) |
2008-12-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00064246 |
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder |
https://ClinicalTrials.gov/show/NCT00064246 |
Completed |
National Cancer Institute (NCI) |
2004-09-30 |
| NCT00062244 |
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00062244 |
Completed |
National Cancer Institute (NCI) |
2007-06-30 |
| NCT00058240 |
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma |
https://ClinicalTrials.gov/show/NCT00058240 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00058227 |
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00058227 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00054639 |
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00054639 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00054483 |
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00054483 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00045695 |
Bortezomib in Treating Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00045695 |
Completed |
National Cancer Institute (NCI) |
2006-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00020800 |
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00020800 |
Completed |
Jonsson Comprehensive Cancer Center |
2003-04-30 |
| NCT00017381 |
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00017381 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00006473 |
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006473 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00005579 |
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom’s Macroglobulinemia, or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00005579 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00398710 |
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00398710 |
Completed |
AEterna Zentaris |
2011-08-31 |